Showcasing Development & Application of Antibody Dual Drugs Conjugation (AD2C) Platform - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Showcasing Development & Application of Antibody Dual Drugs Conjugation (AD2C) Platform

11:30 am - Wednesday 14th October 2026

Introducing the advantages and differentiation of AD2C platform for ADC development
Applying AD2C platform in development of anti-GPC3 ADCs with dual payloads for hepatocellular carcinoma treatment

Speakers:

Sonny Hsiao

Sonny Hsiao

Founder & Chief Executive Officer

Acepodia Biotech